SCHEMBL3573605

SCHEMBL3573605

COc1ccc(NC=C2C(=O)Nc3cc(C(=O)c4ccc(NC(C)=O)cc4)ccc32)cc1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX4 Q9NPH5 1/20 0.48
GSK3B P49841 4/20 0.45
RET P07949 3/20 0.43
FLT4 P35916 3/20 0.42
KDR P35968 3/20 0.42
FLT3 P36888 3/20 0.42
JAK3 P52333 1/20 0.41
MAPT P10636 2/20 0.41
CYP3A4 P08684 1/20 0.41
LRRK2 Q5S007 1/20 0.40
NTRK3 Q16288 2/20 0.39
CHEK1 O14757 2/20 0.39
KIT P10721 1/20 0.39
AURKB Q96GD4 2/20 0.39
PLK4 O00444 1/20 0.39
MAPK13 O15264 1/20 0.39
PDPK1 O15530 1/20 0.39
DAPK3 O43293 1/20 0.39
DYRK3 O43781 1/20 0.39
PRKD3 O94806 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3573600 1.00 NOX4 (0.48) NOX4GSK3BRETFLT4KDR
SCHEMBL3575834 0.93 NOX4 (0.47) NOX4GSK3BRETFLT4KDR
SCHEMBL3575839 0.93 NOX4 (0.47) NOX4GSK3BRETFLT4KDR
SCHEMBL3572826 0.91 FLT4 (0.43) NOX4RETFLT4KDRFLT3
SCHEMBL3572834 0.90 CHEK1 (0.41) NOX4RETFLT4KDRFLT3
SCHEMBL3581700 0.88 JAK3 (0.43) NOX4GSK3BFLT4KDRFLT3
SCHEMBL3581696 0.88 JAK3 (0.43) NOX4GSK3BFLT4KDRFLT3
SCHEMBL3572683 0.86 FLT3 (0.43) NOX4RETFLT4KDRFLT3
SCHEMBL4758595 0.86 NOX4 (0.54) NOX4GSK3BRETJAK3LRRK2
SCHEMBL4758589 0.86 NOX4 (0.54) NOX4GSK3BRETJAK3LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP claimed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US claimed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO claimed
US-7749530-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-07-06 US disclosed
WO-2010075197-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2010-07-01 WO disclosed
US-7692005-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-04-06 US disclosed
US-20090208557-A1 Kinase inhibitors ALLERGAN, INC. 2009-08-20 US disclosed
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP disclosed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US disclosed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090208557-A1 Kinase inhibitors PTK2, MAP3K6, MAP3K20 NOX4 1226/4885GSK3B 491/4885RET 93/4885
US-20070032478-A1 Kinase Inhibitors ABL1, LCK, ERBB2 NOX4 1380/4885GSK3B 478/4885RET 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.